Phase I trial of ADP-A2AFP TCR T-cell therapy in patients with advanced hepatocellular or gastric hepatoid carcinoma

By afschroeder • August 15, 2025

Meyer T, Finn RS, Borad M, Mahipal A, Edeline J, Houot R, Hausner PF, Hollebecque A, Goyal L, Frigault M, Jeffry Evans TR, Wong KM, Tan BR, Mitry E, Sarker D, Feun L, El-Rayes B, Thistlethwaite F, Kaseb A, Alese O, Jin Z, Cirillo C, Bruix J, Roddie C, Noto P, Fayngerts S, Cristiani S, Sampson J, Bai J, Isabelle M, Broad R, Sun A, Norry E, Sangro B. Phase I trial of ADP-A2AFP TCR T-cell therapy in patients with advanced hepatocellular or gastric hepatoid carcinoma. J Hepatol. 2025 Aug 12:S0168-8278(25)02404-3. doi: 10.1016/j.jhep.2025.07.033. Epub ahead of print. PMID: 40812667.

Tags: Adoptive T-cell therapy, alpha-fetoprotein, Hematology/Oncology, Hepatocellular carcinoma, immunotherapy, Publications, T-cell receptor T-cell therapy

IL-9 as a naturally orthogonal cytokine with optimal JAK/STAT signaling for engineered T cell therapy

Jiang H, Limsuwannarot S, Kulhanek KR, Pal A, Labiad O, Rysavy LW, Wong A, Su L, Cavender S, Soro J, Testa S, Ogana H, Waghray[...]

Mammary small cell neuroendocrine carcinomas that showed excellent pathologic response following etoposide-based neoadjuvant chemotherapy

Hammer PM, Enamandram S, Ikeda DM, Lam MM, Wapnir IL, Chamberlain ED, Shaheen S, Caswell-Jin JL, Itakura H, Bean GR. Mammary small cell neuroendocrine carcinomas[...]

Optimal Duration of Androgen Deprivation Therapy With Definitive Radiotherapy for Localized Prostate Cancer: A Meta-Analysis

Zaorsky NG, Sun Y, Nabid A, Zapatero A, Bolla M, Joseph D, Maingon P, Guerrero A, Gonzalez AA, San-Segundo CG, Cabeza Rodríguez MÁ, Sole JM,[...]